Objective:The aim of this study was to investigate the clinical value and relevance on the serum β2-microglobulin(β2-MG) of patients with thyroid cancer.Methods:One thousand and two normal cases,95 thyroid cancer pa...Objective:The aim of this study was to investigate the clinical value and relevance on the serum β2-microglobulin(β2-MG) of patients with thyroid cancer.Methods:One thousand and two normal cases,95 thyroid cancer patients and 243 nodular goiter patients were selected to measure serum β2-MG levels using double-antibody sandwich enzyme-linked immunosorbent assay(ELISA).Results:The positive rate of 7.78% in normal population(78/1002) and 31.57% in thyroid cancer patients(30/95).There were significant differences between the normal population and thyroid cancer patients(χ2 = 55.352;P = 0.000).The positive rate of 7.81% in nodular goiter patients(19/243) and there were no significant differences between the normal population and nodular goiter patients(χ2 = 0.0004;P = 0.986),but significant differences between nodular goiter patients and thyroid cancer patients(χ2 = 31.106;P = 0.000).Meanwhile,the significant difference of the positive rate existed in between the various pathological types of thyroid cancer(χ2 = 10.015;P = 0.007),anaplastic thyroid cancer patients with the highest positive rate and The significant difference was found between the positive lymph node metastasis groups and negative lymph node metastasis groups(χ2 = 4.441;P = 0.035),the presence of distant metastasis group and absence of distant metastasis group(χ2 = 9.795;P = 0.002).Conclusion:Serum β2-MG levels and prognosis of thyroid cancer patients was negatively correlated.It showed important clinical value to detect the level of β2-MG in the early diagnosis,prognosis and the clinical observation for thyroid cancer patients.展开更多
文摘Objective:The aim of this study was to investigate the clinical value and relevance on the serum β2-microglobulin(β2-MG) of patients with thyroid cancer.Methods:One thousand and two normal cases,95 thyroid cancer patients and 243 nodular goiter patients were selected to measure serum β2-MG levels using double-antibody sandwich enzyme-linked immunosorbent assay(ELISA).Results:The positive rate of 7.78% in normal population(78/1002) and 31.57% in thyroid cancer patients(30/95).There were significant differences between the normal population and thyroid cancer patients(χ2 = 55.352;P = 0.000).The positive rate of 7.81% in nodular goiter patients(19/243) and there were no significant differences between the normal population and nodular goiter patients(χ2 = 0.0004;P = 0.986),but significant differences between nodular goiter patients and thyroid cancer patients(χ2 = 31.106;P = 0.000).Meanwhile,the significant difference of the positive rate existed in between the various pathological types of thyroid cancer(χ2 = 10.015;P = 0.007),anaplastic thyroid cancer patients with the highest positive rate and The significant difference was found between the positive lymph node metastasis groups and negative lymph node metastasis groups(χ2 = 4.441;P = 0.035),the presence of distant metastasis group and absence of distant metastasis group(χ2 = 9.795;P = 0.002).Conclusion:Serum β2-MG levels and prognosis of thyroid cancer patients was negatively correlated.It showed important clinical value to detect the level of β2-MG in the early diagnosis,prognosis and the clinical observation for thyroid cancer patients.
